Heather J. Sutherland

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia.

Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia.

Journal: Leukemia research
Published: April 30, 2026

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Journal: Blood advances
Published: August 18, 2025

Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias.

Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias.

Journal: Blood advances
Published: August 18, 2025

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy.

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy.

Journal: Transplantation and cellular therapy
Published: July 10, 2025

Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies.

Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies.

Journal: British journal of haematology
Published: March 18, 2025

Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.

Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.

Journal: Acta haematologica
Published: May 03, 2024

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.

Journal: Vaccine
Published: February 29, 2024

Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products.

Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products.

Journal: Cytotherapy
Published: November 17, 2023

Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.

Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.

Journal: Leukemia
Published: September 04, 2023

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 04, 2023

Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.

Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.

Journal: EJHaem
Published: June 21, 2022

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.

Journal: Leukemia
Published: March 21, 2022
Showing 1-12 of 39

Last Updated: 09/26/2026